when was semaglutide discovered Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions Novo cuts GLP-1 prices 70%,

8 Societal changes driven by uptake of GLP-1 weight loss medications The sweeping changes in food preference and appetite brought on by GLP-1RA pharmacotherapies are producing extensive downstream effects that reach beyond the individual, shaping broader cultural, social, and economic landscapes

Strategy 3: address GI symptoms aggressively Do not accept persistent nausea as an inevitable cost of treatment

Eligibility for liraglutide for weight loss is: Body Mass Index BMI 30 or higher or 27 or higher with weight related condition

Early research suggests that taking L-carnitine by mouth along with these drugs for 4 weeks reduces the risk for liver damage

Use of GLP-1 agonists is becoming increasingly more common in the U.S

This is where outcomes change